Indian patent filing targets next-generation psychedelics for addiction treatment

03/27/2026 – 07:32

Vancouver, Canada, March 27, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second-generation, neuroplastogenictherapeutics – derived to solve major health problems under-treated, today announced the filing of a patent application in India covering innovative next-generation psychedelic-based compounds for the treatment of mental health disorders and addiction.

The patent application, filed with the Indian Patent Office, forms part of the Company’s global intellectual property portfolio and builds on an exclusive worldwide license agreement with the Yissum Research Development Company of the Hebrew University of Jerusalem. It promotes new compounds designed to overcome the limitations of classic psychedelics, offering safer, more effective, and scalable treatment options for underserved mental health conditions and addictive disorders.

regarding Clearmind Medicine Inc.

Clearmind is a clinical stage neuroplastogen pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogenicderivative therapy to solve widespread and underserved health problems, including alcohol use disorders. Its main goal is to research and develop psychedelic-based compounds and try to commercialize them as drugs, foods, or regulated supplements.

company‘s intellectual portfolio now consists of nineteen patent families, including 31 patents granted. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property rights to build its portfolio.

Shares of Clearmind listed for trading on the Nasdaq under the symbol “CMND.”

For more information, please visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com

Expectant statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Such words “hope,“”anticipation,“”intention,“”plan,“”believe,“”search,“”OUTLOOK” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company uses forward-looking statements when discussing it expanding the global intellectual portfolio. The Company cannot guarantee that any patent will problem the result a patent pending apor, if issued, whether it will issue in a form that will be beneficial to the Company. Forward-looking statements are not historical facts, and are based on management‘s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there is no guarantee that the management‘s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is stated in or indicated by forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company‘s reports filed from time to time with the Securities and Exchange Commission (“SEC“), including, but not limited to, risk detail in the Company‘annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statement is made. The company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference is necessary picture that the Company will make additional updates related to it or related to other forward-looking statements. References and links to websites have been provided as a convenience, and information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the content of third party websites.

FAQ

What did Clearmind (CMND) announce on March 27, 2026 about patents in India?

Clearmind announces patent application in India for next generation neuroplastogen compound. According to the company, the filing with the Indian Patent Office protects a novel, non-hallucinogenic compound aimed at treating mental health and addiction.

How does the Indian patent application affect Clearmind’s intellectual position for CMND?

The Indian filing expands Clearmind’s global IP footprint for its neuroplastogen program. According to the company, it completes the existing worldwide rights under an exclusive license with Yissum and targets local patent protection.

Does Clearmind’s (CMND) patent application cover psychedelic compounds that are non-hallucinogenic?

Yes. The application seeks protection for next-generation, non-hallucinogenic psychedelic-based compounds. According to the company, these are designed to overcome the limitations of classic psychedelics and offer a safer treatment.

Which disorder does Clearmind (CMND) claim an Indian patent to target for treatment?

Filing targets mental health disorders and addiction with neuroplastogen-derived therapies. According to the company, this compound is intended to address underserved mental health conditions and addictive disorders.

What does the Indian patent have to do with the Clearmind license from Yissum for CMND?

Filing is built under the exclusive worldwide license of Clearmind from Yissum. According to the company, the Indian app is part of its IP portfolio derived from that licensed technology.